What was Merck's revenue in Q1 2026?

Merck reported revenue of $16.3 billion in Q1 2026, up 5% year over year.

What drove Merck's revenue growth?

Oncology, particularly Keytruda, was the main growth driver, along with contributions from new products like Winrevair.

Merck Reports Q1 2026 Revenue of $16.3 Billion, Up 5%

Q: Did Merck provide guidance for the next quarter?

Merck did not provide specific quarterly guidance but indicated expectations for continued growth.

Merck & Co., Inc. (NYSE:MRK) reported first-quarter 2026 revenue of $16.3 billion, up 5% year over year. The company highlighted continued oncology momentum, growing contributions from newer launches, and a series of regulatory and pipeline milestones.

Merck & Co., Inc. (NYSE:MRK) reported first-quarter 2026 revenue of $16.3 billion, up 5% year over year. The company attributed growth to strong oncology performance and increasing contributions from recently launched products, along with several regulatory and pipeline achievements.

Key Financial Results

Metric	Q1 2026	YoY Change
Revenue	$16.3B	+5%
Net Income	Not disclosed	-
EPS	Not disclosed	-

Highlights from the Call

Management confirmed sustained momentum in the oncology portfolio, particularly with Keytruda remaining the primary revenue driver. New products such as Winrevair (for pulmonary arterial hypertension) also contributed to growth. The quarter saw new regulatory approvals and expanded indications.

Guidance

The company did not provide specific quarterly guidance but indicated expectations for continued growth supported by a strong pipeline.

Stock Impact

No stock reaction was mentioned in the report, but positive results could support the stock in the near term.

What This Means for Investors

The results demonstrate Merck's continued strength in oncology, with diversifying revenue streams from new products. Investors should monitor pipeline developments and future regulatory approvals.